Cargando…

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Fenfluramine, tradename Fintepla(®), was appraised within the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process as Technology Appraisal 808. Within the STA process, the company (Zogenix International) provided NICE with a written submission and a math...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijnen, Ben, Witlox, Willem, Wolff, Robert, Fayter, Debra, Ramaekers, Bram, Otten, Thomas, Ryder, Steve, Posadzki, Pawel, Worthy, Gill, Stirk, Lisa, Armstrong, Nigel, Kleijnen, Jos, Joore, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813053/ https://www.ncbi.nlm.nih.gov/pubmed/36301414 http://dx.doi.org/10.1007/s40273-022-01209-8

Ejemplares similares

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2019)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2022)

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Otten, Thomas, et al.
Publicado: (2023)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2020)

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem J. A., et al.
Publicado: (2019)

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2018)

Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2018)

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2022)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2019)

Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma: An Evidence Review Group Evaluation of the NICE Single Technology Appraisal
por: Thielen, Frederick W., et al.
Publicado: (2018)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Witlox, Willem, et al.
Publicado: (2023)

Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020)

A review of fenfluramine for the treatment of Dravet syndrome patients
por: Simon, Kayla, et al.
Publicado: (2021)

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2018)

Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome
por: Millett, David, et al.
Publicado: (2021)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021)

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: van Asselt, Antoinette D. I., et al.
Publicado: (2023)

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2017)

An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
por: Guerrini, Renzo, et al.
Publicado: (2022)

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
por: Zhang, Yifan, et al.
Publicado: (2015)

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2023)

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial
por: Nabbout, Rima, et al.
Publicado: (2020)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)

Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
por: Schoonjans, A., et al.
Publicado: (2016)

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
por: Grimm, Sabine E., et al.
Publicado: (2021)

Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance
por: Westwood, Marie, et al.
Publicado: (2017)

Fenfluramine: a plethora of mechanisms?
por: Sourbron, Jo, et al.
Publicado: (2023)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

The relationship between Lp(a) and CVD outcomes: a systematic review
por: Forbes, Carol A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_691roma2ih0obplr3c5cu4hkkr